{"url_path":"/sec/xlo/8-k/2026-05-12/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-218194-index.html","accession_number":"0001193125-26-218194","cik":"0001840233","ticker":"XLO","issuer_name":"Xilio Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1840233/0001193125-26-218194-index.html","primary_entity_key":"0001840233","primary_entity_name":"Xilio Therapeutics, Inc."},"word_count":146,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\n \n\nOn May 12, 2026, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.\n\n \n\nThe information in this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}